S Company for Science.

This will greatly help Singapore's preparedness to create vaccines quickly, safely and economically in theevent of a flu epidemic.This could potentially open doorways for faster production of vaccines to a range of viral diseases aswell. .. A*Celebrity, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine Singapore's Company for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that the initial healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine applicant predicated on Cytos' proprietary bacteriophage Qbeta virus-like particle technology. In this first Phase 1 clinical trial, the safety and immunogenicity of the novel vaccine applicant and its potential to protect against H1N1 influenza disease will become evaluated.An archived webcast of the conference contact will be available under the Investor Relations section of the Company’s website at.

Abbott Reviews 14.4 Percent Sales Growth in Third Quarter Worldwide Pharmaceutical Sales Increased 19.6 Percent. Worldwide Medical Products Product sales Elevated 12.0 Percent. International Nutritionals Sales Increased 15.6 Percent. Organization Confirms Earnings-Per-Talk about Outlook for 2007 and 2008. Abbott announced monetary results for the 3rd quarter ended September 30, 2007. Diluted earnings per share, excluding specified items, were $0.67, above Abbott’s previously announced guidance selection of $0.64 to $0.66. Diluted earnings per talk about under Generally Accepted Accounting Concepts were $0.46. Based on its strong outcomes year to day, Abbott is definitely confirming its 2007 earnings-per-talk about outlook and raising the low end of its prior guidance range.